Welcome to our dedicated page for Terumo news (Ticker: TRUMY), a resource for investors and traders seeking the latest updates and insights on Terumo stock.
Terumo Corporation news covers medical technology developments reported through its U.S. device and digital health businesses. Recurring updates include Terumo Neuro products for cerebral aneurysms, ischemic stroke, carotid artery disease and neurovascular malformations, including the SOFIA™ catheter line and carotid stent systems used in neurovascular procedures.
Company announcements also cover Terumo Interventional Systems and Terumo Health Outcomes activity in minimally invasive cardiovascular treatment, coronary physiology software, clinical decision support, hemodynamic monitoring, FDA clearances and approvals, commercial launches, distribution agreements and clinical data presented at medical meetings.
Terumo Corporation (TSE: 4543) has pledged an additional USD 1 million to the COVID-19 Solidarity Response Fund for the WHO, marking its second contribution since April 2020. This donation aims to bolster vaccine equity efforts in low-income countries, which have received less than 1% of global vaccine distributions. The fund, over its first year, has mobilized USD 250 million for essential COVID-19 research, treatments, and supplies. Shinjiro Sato, CEO, emphasized the importance of equitable healthcare during these challenging times.
Terumo Blood and Cell Technologies and CSL Plasma have announced a collaboration to develop a new plasma collection platform at CSL Plasma's U.S. collection centers. A clinical trial for the investigational plasmapheresis device commenced in April 2021. The introduction of this platform is contingent on U.S. FDA device clearance, with further details to follow. Plasma collected plays a crucial role in therapies for life-threatening conditions, including immune deficiencies and hemophilia. CSL Plasma operates over 300 centers globally, providing vital therapies to patients.
Terumo has launched its Global Therapeutic Interventional Oncology team as of April 1, 2021, aiming to enhance cancer treatment solutions. This specialized team focuses on Medical Strategy, Research & Development, and Software Development, and will be led by Laurent Domas. With a growing demand for minimally invasive treatments, Terumo plans to extend its Holmium platform in regions including the US and China, addressing the rise in cancer cases.
Terumo Corporation (TSE: 4543) announced its definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS), a leader in predictive analytics for healthcare. This acquisition aims to enhance Terumo's digital healthcare capabilities through the ePRISM® platform, which delivers personalized insights for treatment. Expected to close in February 2021, the deal represents a strategic opportunity for Terumo to reduce healthcare costs and improve patient outcomes worldwide. HOS's technology will integrate into Terumo's Business Edge unit, reinforcing its commitment to precision medicine.
Terumo Corporation (TSE: 4543) has completed a clinical study in Japan for an automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. The study initiated in February 2020 aimed to assess the safety of the device combined with G-Lasta®, a drug that reduces febrile neutropenia in chemotherapy patients. This investigational product allows for administration on the same day as chemotherapy, potentially easing hospital visits for patients. Terumo aims to enhance healthcare delivery through innovative drug delivery systems.
IceCure Medical Ltd. (TASE: ICCM) announced an expanded partnership with Terumo Corporation (TRUMY: OTC US) to enhance its reach in Southeast Asia. The agreement grants Terumo exclusive distribution rights for IceCure's ProSense™ cryoablation system in Thailand for six years, with a potential extension. The deal includes a $450,000 payment, with an initial purchase order worth $329,000. IceCure aims to address the high cancer incidence in Thailand, where approximately 170,000 cases are reported annually, leveraging its minimally invasive technology for effective tumor treatment.